ECSP055851A - Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis - Google Patents
Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesisInfo
- Publication number
- ECSP055851A ECSP055851A EC2005005851A ECSP055851A ECSP055851A EC SP055851 A ECSP055851 A EC SP055851A EC 2005005851 A EC2005005851 A EC 2005005851A EC SP055851 A ECSP055851 A EC SP055851A EC SP055851 A ECSP055851 A EC SP055851A
- Authority
- EC
- Ecuador
- Prior art keywords
- angiogenesis
- treatment
- pirazinona
- indolil
- derivatives
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 230000033115 angiogenesis Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 230000003463 hyperproliferative effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42549002P | 2002-11-12 | 2002-11-12 | |
| US46091503P | 2003-04-07 | 2003-04-07 | |
| US48420203P | 2003-06-30 | 2003-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP055851A true ECSP055851A (es) | 2005-09-20 |
Family
ID=32314888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2005005851A ECSP055851A (es) | 2002-11-12 | 2005-06-10 | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1565455A1 (de) |
| JP (1) | JP2006509840A (de) |
| KR (1) | KR20050072824A (de) |
| AR (1) | AR043059A1 (de) |
| AU (1) | AU2003290744A1 (de) |
| BR (1) | BR0316169A (de) |
| CA (1) | CA2505819A1 (de) |
| EC (1) | ECSP055851A (de) |
| HR (1) | HRP20050496A2 (de) |
| MA (1) | MA27557A1 (de) |
| MX (1) | MXPA05004779A (de) |
| NO (1) | NO20052796L (de) |
| PE (1) | PE20040832A1 (de) |
| PL (1) | PL376867A1 (de) |
| TW (1) | TW200418834A (de) |
| UY (1) | UY28074A1 (de) |
| WO (1) | WO2004043950A1 (de) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| NZ546990A (en) | 2003-11-20 | 2010-03-26 | Janssen Pharmaceutica Nv | 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| NZ546991A (en) * | 2003-11-20 | 2010-01-29 | Janssen Pharmaceutica Nv | 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as PARP inhibitors |
| JP2007512331A (ja) * | 2003-11-21 | 2007-05-17 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 過剰増殖性疾患および血管新生に関連した病気の治療に有用なインドリル−チエノ’３，４−ｂ！ピラジン−３−オン誘導体 |
| US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| JP5100376B2 (ja) | 2004-06-30 | 2012-12-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐ阻害剤としてのキナゾリンジオン誘導体 |
| CA2568835C (en) | 2004-06-30 | 2014-05-27 | Janssen Pharmaceutica N.V. | Quinazolinone derivatives as parp inhibitors |
| WO2006003147A1 (en) | 2004-06-30 | 2006-01-12 | Janssen Pharmaceutica N.V. | Phthalazine derivatives as parp inhibitors |
| JP6097946B2 (ja) * | 2004-11-17 | 2017-03-22 | レクサン ファーマシューティカルズ インコーポレイテッド | １−［（６，７−置換−アルコキシキノキサリニル）アミノカルボニル］−４−（ヘテロ）アリールピペラジン誘導体 |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| US7897762B2 (en) * | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| JP5545955B2 (ja) | 2007-03-08 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体 |
| DK2271626T3 (en) | 2008-03-27 | 2015-02-23 | Janssen Pharmaceutica Nv | TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN |
| WO2010053757A1 (en) * | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
| WO2010074807A1 (en) | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators |
| US20100120778A1 (en) * | 2008-11-07 | 2010-05-13 | Wyeth | Quinoxaline-based lxr modulators |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| BR112016022056B1 (pt) | 2014-03-26 | 2023-04-11 | Astex Therapeutics Limited | Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico |
| US10736900B2 (en) | 2014-03-26 | 2020-08-11 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
| CN106458934B (zh) * | 2014-04-18 | 2019-08-16 | 米伦纽姆医药公司 | 喹喔啉化合物及其用途 |
| EP3247705B1 (de) | 2015-01-20 | 2019-11-20 | Millennium Pharmaceuticals, Inc. | Chinazolin- und chinolinverbindungen und verwendungen davon als nampt inhibitoren |
| TWI719960B (zh) | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| WO2017050865A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| HUE050567T2 (hu) | 2015-09-23 | 2020-12-28 | Janssen Pharmaceutica Nv | Triciklusos heterociklusok rák kezelésére |
| WO2023050007A1 (en) * | 2021-09-29 | 2023-04-06 | Repare Therapeutics Inc. | N-(5-substituted-[(1,3,4-thiadiazolyl) or (thiazolyl)])(substituted)carboxamide compounds and use thereof for inhibiting human polymerase theta |
| KR20250108598A (ko) * | 2022-09-29 | 2025-07-15 | 리페어 세라퓨틱스 인크. | N-(5-치환된-[(1,3,4-티아다이아졸릴) 또는 (1,3-티아졸릴)](치환된)카복스아마이드 화합물, 약제학적 조성물, 그리고 아마이드 화합물의 제조 방법 및 이의 용도 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW472045B (en) * | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
| AU1918299A (en) * | 1998-02-23 | 1999-09-06 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
-
2003
- 2003-11-05 AR ARP030104059A patent/AR043059A1/es unknown
- 2003-11-10 CA CA002505819A patent/CA2505819A1/en not_active Abandoned
- 2003-11-10 WO PCT/US2003/036003 patent/WO2004043950A1/en not_active Ceased
- 2003-11-10 MX MXPA05004779A patent/MXPA05004779A/es not_active Application Discontinuation
- 2003-11-10 KR KR1020057008396A patent/KR20050072824A/ko not_active Withdrawn
- 2003-11-10 PL PL376867A patent/PL376867A1/pl unknown
- 2003-11-10 EP EP03783328A patent/EP1565455A1/de not_active Withdrawn
- 2003-11-10 HR HR20050496A patent/HRP20050496A2/hr not_active Application Discontinuation
- 2003-11-10 JP JP2005507146A patent/JP2006509840A/ja active Pending
- 2003-11-10 BR BR0316169-2A patent/BR0316169A/pt not_active Application Discontinuation
- 2003-11-10 AU AU2003290744A patent/AU2003290744A1/en not_active Abandoned
- 2003-11-11 UY UY28074A patent/UY28074A1/es not_active Application Discontinuation
- 2003-11-11 TW TW092131443A patent/TW200418834A/zh unknown
- 2003-11-11 PE PE2003001136A patent/PE20040832A1/es not_active Application Discontinuation
-
2005
- 2005-06-09 NO NO20052796A patent/NO20052796L/no not_active Application Discontinuation
- 2005-06-09 MA MA28322A patent/MA27557A1/fr unknown
- 2005-06-10 EC EC2005005851A patent/ECSP055851A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20052796D0 (no) | 2005-06-09 |
| PE20040832A1 (es) | 2005-01-27 |
| TW200418834A (en) | 2004-10-01 |
| UY28074A1 (es) | 2004-05-31 |
| HRP20050496A2 (en) | 2006-06-30 |
| MA27557A1 (fr) | 2005-10-03 |
| KR20050072824A (ko) | 2005-07-12 |
| JP2006509840A (ja) | 2006-03-23 |
| AU2003290744A1 (en) | 2004-06-03 |
| MXPA05004779A (es) | 2005-07-22 |
| PL376867A1 (pl) | 2006-01-09 |
| CA2505819A1 (en) | 2004-05-27 |
| AR043059A1 (es) | 2005-07-13 |
| WO2004043950A1 (en) | 2004-05-27 |
| EP1565455A1 (de) | 2005-08-24 |
| BR0316169A (pt) | 2005-09-27 |
| NO20052796L (no) | 2005-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28074A1 (es) | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiperproliferativos | |
| ECSP045081A (es) | Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados | |
| UY29983A1 (es) | Derivados de 4-amino-pirrolotriazina sustituida utiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogenesis | |
| ECSP055899A (es) | Pirimidinas inhibidoras de chk, pdk y akt, su producción y su uso como agentes farmacéuticos | |
| SV1999000047A (es) | Nuevas dihidropirimidinas fef. lea 32792-sv | |
| UY28014A1 (es) | Compuestos quimicos | |
| PT1485127E (pt) | Administração de agentes para o tratamento de inflamação | |
| UY28314A1 (es) | Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad | |
| UY28290A1 (es) | Compuestos farmacéuticos novedosos | |
| ECSP045156A (es) | Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6 | |
| ECSP088283A (es) | Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
| PA8565901A1 (es) | Derivados de dihidrobenzodiazepin-2-ona iii | |
| CR9034A (es) | Preparacion y uso de derivados de acido bifenil-4-il-carbonilamino para el tratamiento de la obesidad | |
| ECSP066717A (es) | Compuestos de quinolina sustituidos | |
| PA8543301A1 (es) | Derivados de dihidro-benzo (b) (1,4) diazepin-2 -ona como antagonistas ii mglur2 | |
| HN2004000319A (es) | "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia" | |
| DOP2002000429A (es) | Imidazotriazinas | |
| HN2003000080A (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso | |
| CY1109992T1 (el) | Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα | |
| HN2003000379A (es) | Derivados de anilinopirazol utiles en el tratamiento de la diabetes | |
| UY27203A1 (es) | Bencimidazoles útiles en el tratamiento de la disfunción sexual | |
| EP1585519A4 (de) | Hochkonzentrierte formulierungen vonopioiden und opiod-derivaten | |
| ECSP056174A (es) | Acidos hidroxamicos utiles en el tratamiento detrastornos hiperproliferativos | |
| TW200621703A (en) | Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | |
| SV2003001061A (es) | Nuevos heterociclos 3 ref.lea 35361-sv |